The findings support Foundation's algorithm, called HRDsig, as a strong predictor of response to PARP inhibition.

The company will partner separately with Invivoscribe and AccuraGen for the development of cancer biomarker and minimal residual disease tests.

The results add to evidence for the potential of ctDNA tumor fraction as a new monitoring tool that could allow clinical researchers to detect tumor progression and change treatment strategies earlier than through current methods.

Immunotherapy has transformed cancer treatment in just a few years, and studies presented at the AACR Annual Meeting show how proteomics will further unlock immunotherapy’s potential and help bring the next generation of therapies to market.

DNA methylation analysis in the blood, powered by advances in wet-lab chemistry and bioinformatics, has enabled the use of epigenomic profiling to enhance the sensitivity of liquid biopsy, providing a deeper understanding of tumor biology and expanding the promise of precision oncology beyond what genomic information can offer.

For the benefits of precision medicine to be fully realized, more laboratories must be able to access NGS technologies in-house, and NGS results must be delivered to patients faster.

Illumina’s new software platform, designed to reduce tertiary analysis time and ease reporting, launches in multiple global markets as experts say the volume of clinical NGS data is ballooning. 

In the wake of a transformational period for bladder cancer treatment, the time is right to harness integrated care coordination and precision medicine in order to optimize patient outcomes across the disease continuum.